Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Amicus Therapeutics Affirms FY2025 Sales Guidance of $607.539M-$644.520M vs $620.675M Est

Author: Benzinga Newsdesk | July 31, 2025 07:14am

2025 Financial Guidance

Amicus reiterates its financial guidance for 2025, as follows:

Total Revenue Growth1	15% to 22%
Galafold Revenue Growth1	10% to 15%
Pombiliti + Opfolda Revenue Growth1	50% to 65%
Gross Margin	Mid 80%
Non-GAAP Operating Expenses4	$380M to $400M	(Incl. $30M Upfront License Payment)
GAAP Net Income	Positive during H2 2025

Posted In: FOLD